INTRODUCTION
The Th17 cells, a subpopulation of T-helper cells characterized by high production of the cytokines interleukin (IL)-17A and IL-17F, are associated with the induction of autoimmunity and have important roles in the pathogenesis of rheumatoid arthritis (RA) (1) . In the rheumatoid synovium, Th17 cells are enriched and produce bioactive IL-17 in response to stimulation. The produced IL-17 amplifies the inflammation induced by other cytokines, particularly tumor necrosis factor (TNF) and IL-1 (2, 3) , and induces extensive inflammatory cell migration and massive cartilage and bone degradation (4) . The prevalence of IL-17 producing CD4 T-cells is increased in the circulation of RA patients (5) and correlates to the number of swollen joints and to systemic inflammation (6) . Importantly, a reduction of circulating Th17 cells has been a suggested prerequisite of clinically efficient treatment in RA (7) (8) (9) . IL-17 was targeted in several clinical studies for RA (10) . Currently, clinical trials with monoclonal antibodies against IL-17 and IL-17 receptor report a favorable therapeutic effect in patients with severe arthritis (11) (12) (13) .
It has been postulated and experimentally proven that Th17 cells may differentiate to functionally distinct cells depending on cytokines directing their development (14) . An inflammatory envi-
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Karin M E Andersson, 1 Nicola Filluelo Cavallini, 1 Dan Hu, 2 Mikael Brisslert, 1 Ron Cialic, 2 Hadi Valadi, 1 Malin C Erlandsson, 1 Sofia Silfverswärd, 1 Rille Pullerits, 1 Vijay K Kuchroo, 2 Howard L Weiner, 2 and Maria I Bokarewa ronment in RA abundant with IL-1β and IL-6 is associated with maturation of Th17 cells from naive and Foxp3 + regulatory T cells (15) (Tregs) and is characterized by surface expression of C-C chemokine receptor type 6 (CCR6), the induction of master transcription factor RAR-related orphan receptor gamma of T cells (RORγt) and production of signature cytokines IL-17A/IL-17F. Several transcription phases define development of Th17 (16) , where production of IL-21 is characteristic of mature Th17 cells, acting as an amplification factor inducing expansion of Th17 cells and the expression of IL-23R. The expression of IL-23R has strong linkage to inflammation and has been shown to be critical for the pathogenic phenotype of Th17 cells (17, 18) . It is often accompanied by high production of the proinflammatory cytokines IL-22, TNF and granulocyte-monocyte colonystimulating factor (GM-CSF). In healthy subjects, differentiation of Th17 cells is often controlled by combination of IL-6 and transforming growth factor (TGF)-β, and the balance with proinflammatory signaling may reprogram them to the Treg phenotype (19) . CCR6 appears to be the dominant receptor for the migration of Th17 cells to secondary lymphoid organs (20) . The expression of CCR6 has been shown on autoreactive memory T cells (21) . CCR6-expressing Th17 cells are preferentially recruited to the inflamed joints of RA patients attracted by large amounts of C-C chemokine ligand type 20 (CCL20) produced by rheumatoid T cells and synoviocytes (22 
MATERIALS AND METHODS

Patients
Blood samples were obtained from 33 patients (28 women, 5 men) with established RA. Clinical characteristics of the patients are presented in Figure 1A . The patients fulfilled the American College of Rheumatology 1987 revised criteria for RA (24) and had a duration of disease of 17 years (range 9-47 years). All RA patients obtained regular treatment with monoclonal anti-TNF antibodies (infliximab, 3-5 mg/kg every 8 wks). A total of 29 patients were also treated with methotrexate (median dose 15 mg/ week), 2 patients were treated with azathioprine (150 mg/day), 1 patient with salazopyrin and 1 patient with mycophenolate mofetil (2 g/day). Clinical activity of RA was calculated at the time of blood sampling based on the number of swollen and tender joints, erythrocyte sedimentation rate (ESR) and global health assessment of the patient, and the disease activity score (DAS28) was constructed (25 
Flow Cytometry
The cells were prepared and stained for the fluorescence-activated cell sorter (FACS) analysis as previously described (26) . Anti-CD4 (GK1.5), anti-CD27 (L128), and anti-C-X-C chemokine receptor 5 (anti-CXCR5; 2G8) were purchased from BD Biosciences; anti-CD19 (H1B19), anti-CD45RA (HI100), anti-CCR6 (G034E3), and anti-CXCR3 (G025H7) from BioLegend. Intracellular staining for Bcl-6 was performed as previously described (27), with anti-Bcl-6 (K112-91) and isotype control (mouse IgG1κ, MOPC-21), both from BD Biosciences. For blocking of unspecific binding via Fc receptors, polyclonal rabbit F(ab')2 anti-human immunoglobulin was added to cells before staining. Fluorochrome minus one (FMO) was used to determine negatively and positively stained populations when needed (28) . Cells were collected, 5 × 10 5 events/sample, using a FACSCanto II (BD Bioscience) equipped with FACSDiva software. The analysis was performed using FlowJo software (version 10.0.6, Tree Star, Inc.).
Compensation for fluorochrome interferences was done using single-stained CompBeads (BD Bioscience).
Gene Expression Analysis
RNA samples were prepared from cell lysates in Buffer RLT by using an RNeasy Mini Kit (Qiagen), according to the manufacturer's instructions. The prepared RNA samples were analyzed with an nCounter Analysis System (NanoString Technologies) by using an HuTh17 CodeSet containing 419 genes. The obtained raw data were normalized with NanoString's nSolver™ analysis program by using the transcription of β2-microglobulin, ribosomal protein L3 (RPL3) and β-actin as housekeeping genes. A total of 387 genes, for which maximum expression level was above noise background, were selected for further analysis. The complete list of these genes is available on request.
Cytokine Production
Analysis of the cytokine production in the CCR6 + CXCR3 -CD4 + cultures was carried out by using Proteome Profiler™ Array, Human Cytokine Array Panel A (ARY005, RnD Systems), according to manufacturer's instructions. Equal amounts of culture medium were mixed with a cocktail of biotinylated detection antibodies. The mix was incubated with the array membrane to allow cytokine antibody complexes in the sample to bind to anti-cytokine antibodies captured on the membrane. After washing away unbound material, a streptavidin-horseradish peroxidase complex was added and detection of array spots was performed by using the Chemi Reagent Mix from the kit. Chemiluminescent signals were visualized and quantified by the Chemidoc equipment and Quantity-One software (Bio-Rad Laboratories). Pixel densities were normalized to reference spots on the membrane.
Statistical Analysis
The values are presented as median and range. The mean expression for each gene of 14 RA patients and 6 controls was calculated and compared by unpaired t test. The difference in groups was calculated as ratio. The ratio >1.5 and p value <0.05 indicated significant difference in gene expression. The pathway analysis was performed by using an Ingenuity IPA 5.5.1 program (Ingenuity) and publicly available databases. Figure 2A ). Cytokine profile array proved a significant enrichment of the cell supernatants with Th17 signature cytokines IL-17, GM-CSF ( Figure 2B ) and chemokine CCL5. The supernatants of RA patients contained high levels of TNF, IL-2 and PAI-1 compared with healthy controls, which verified proinflammatory and a readily proliferating phenotype of these cells. The production of cytokines characteristic for other Th subtypes (interferon [IFN]-γ, IL-13 [ Figure 2B ], IL-12p70 and MIF [not shown]) were on low levels and showed no differences for the supernatants of RA patients and controls. Notably, the mechanisms of Tbet upregulation in Th17 cells were independent of IFNγ, since intracellular media-tors of IFNγ signaling (IRF7 and A20) were repressed (Figure 2A ). The analysis of transcriptional profile of the effectors that polarize the differentiation of Th17 cells was carried out as reported (17) . RA patients had increased production of IL-23 with autocrine stimulation of IL-23R and activation of its intracellular mediator Janus kinase 2 (JAK2), enhancing further the expression of CCL20 and proinflammatory cytokines IL-22, GM-CSF (CSF2 gene), TNF and lymphotoxin-α (Figure 2A ). This autocrine IL-23A stimulation could be traced both in the patients with high IL-17A/IL-17F and RORγt and in those without. Figures 3A, 4B) . The key determinants of Tregs, Foxp3 and IL2RA, were similarly expressed in RA patients and in healthy controls, and they had similar low expression and protein levels of the suppressive cytokine IL-10 ( Figures 3A, 2B) . Interestingly, the expression of Foxp3 within individual patients was almost always discordant to the expression of the canonical Th17 regulator, RORγt ( Figure 3B ), and correlated negatively to IL-23A (r = -0.50, p = 0.02). Transcription pattern of signature cytokines IL-17 and IL-10 repeated the display of transcription factors ( Figure 3B ). TGFβ and IL-1 signaling pathways are common for regulation of Th17 and Treg development (14) . In RA patients, we found high expression of IL1R1 and TGFB2R ( Figure 3A) . The transcriptional and protein levels of their ligands, TGFB ( Figure 3A ) and IL-1α and β (data not shown), were low and consequently led to low expression of the signal transducer and activator of transcription (STAT) family proteins downstream of TGFβ signaling ( Figure 4A ), despite repression of the TGFβ pathway inhibitor Smad7. Nuclear factors of activated T cells (NFAT1 and NFAT2), which induce expression of the Foxp3 gene and function as transcriptional partners of Foxp3, were deregulated and predisposed to dysfunctional Tregs. The suppressors of cytokine signaling (SOCS) family maintaining stability of inducible Tregs (32,33) was also underexpressed in RA patients.
RESULTS
Network Analysis
Overweight of Helios in the Regulatory
The expression of Helios (coded by IKZF2), a marker of thymus-derived Tregs, was higher in RA patients ( Figures 3A, B) . The overweight of Helios was accompanied by surface receptors IL1R1 and T cell immunoreceptor with Ig and ITIM domains (TIGIT), important for suppressive function of Tregs (34) (35) (36) The transcriptional profile of Tfh cells with characteristic transcription of CXCR5, SLAMF-1 and IL-21 was well preserved in RA patients in remission and was significantly higher compared with healthy controls ( Figure 5C ). These markers tended to be even higher in the patients with active RA. The difference in expression of the transcriptional regulator Bcl-6 in RA patients in remission was no longer significant from the healthy controls. Consequently, CCR6 +
CXCR3
-CD4 + cells of RA patients in remission were recognized by somewhat lower expression of chemoattractant CCL20 and lower expression of B-cell-activating cytokines IL-31 and LIF.
DISCUSSION
The present study demonstrates that the peripheral blood CCR6 TBX21 supported by high levels of signature cytokines IL-17A/IL-17F (39). We could follow the complete transcriptional circuit of Th17 differentiation in RA patients enforced by active IL-1R1 and assured production of IL-21. The production of IL-21 is known to be significant, since it acts to induce amplification of differentiating Th17 cells and elicits the expression of IL-23R (17, 40) . This exposure to IL-23 stabilized the Th17 phenotype in RA patients and, together with IL-21, induced production of another proinflammatory cytokine, IL-22 (41) . The late phase of Th17 development is associated with the expression of the regulatory cytokines IL-10 and IL-24 (16, 21) . IL-24 was overexpressed in Th17 cells of RA patients and, together with the increased IL-2 and CD62L, supported formation of memory Th17 cells in the studied RA patients with active disease or in remission. It is important to acknowledge that expression of the dominating effector cytokine had significant intraindividual variations and could be represented by IL-22, IL-23, IL-2, TNF or GM-CSF. This result might reflect heterogeneity of molecular mechanisms engaged in the formation and maintenance of the Th17 profile in RA. Additionally, the pathogenic profile of Th17 cells showed only a limited correlation with the disease activity measured clinically. It was statistically indistinguishable between the patients in remission and those who had clinical signs of active RA. Th17 cells of patients in remission maintained high IL-23R and IL-1R1 expression, the receptors essential for their differentiation (42) 
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